Rhythm Pharmaceuticals, Inc. · NASDAQ:RYTM
Rhythm Pharmaceuticals — Corporate Update (March 2026)
16 slides from Rhythm Pharmaceuticals's corporate update, Mar 19, 2026
Slide 1: IMCIVREE (Setmelanotide) FDA Approval in Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals IMCIVREE (Setmelanotide) FDA Approval in Acquired Hypothalamic Obesity March 19, 2026 ® © Rhythm® Pharmaceuticals, Inc. All rights reserved.
Slide 2: On Today's Call
On Today’s Call • David Connolly, Vice President of Investor Relations and Corporate Communications • David Meeker, MD, Chair, President and Chief Executive Officer • Jennifer Lee, Executive Vice President, Head of North America • Hunter Smith, Chief Financial Officer • Alicia Fiscus, Senior Vice Pr
Slide 3: Forward-looking Statements
Forward-looking Statements This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be
Slide 4: David Meeker, MD
David Meeker, MD Chair, President and CEO ® 4
Slide 5: IMCIVREE now approved for acquired hypothalamic obesity
| . IMCIVREE’ (setmelanotide) injection NOW APPROVED for acquired hypothalamic obesity in people 4 years and older
Slide 6: IMCIVREE: First and Only Therapy Approved for Acquired HO
IMCIVREE: First and Only Therapy Approved for Acquired HO INDICATIONS AND USAGE IMCIVREE is a melanocortin 4 (MC4) receptor agonist indicated to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged: • 4 years and older with acquired hypothalamic obesity (H
Slide 7: Highlights of U.S. Prescribing Information
Highlights of U.S. Prescribing Information DOSAGE AND ADMINISTRATION Recommended starting dosage injected subcutaneously for Adults and Pediatric patients aged 6 years and older with Acquired HO: • 0.5 mg (0.05 mL) once daily for 2 weeks. • 1 mg (0.1 mL) once daily for weeks 3-4. • 2 mg (0.2 mL) onc
Slide 8: Approval Supported By Statistically Significant and Highly Clinically Meaningful BMI Reduction in Phase 3 Acquired HO Trial
Approval Supported By Statistically Significant and Highly Clinically Meaningful BMI Reduction in Phase 3 Acquired HO Trial Primary analysis cohort (N=142) -15.8% -18.4% +2.6% BMI change from baseline in Placebo-adjusted BMI change from baseline in Setmelanotide arm difference in BMI reduction Place
Slide 9: Advancing MC4R Agonism in Acquired Hypothalamic Obesity
Advancing MC4R Agonism in Acquired Hypothalamic Obesity U.S. FDA approval for Acquired Hypothalamic Obesity 2022 2023 2024 2025 2026 • Achieved proof of • Initiated • Positive Phase 3 • EMA regulatory review ongoing; CHMP concept (POC) in global Phase 3 TRANSCEND trial opinion expected in Q2 setmela
Slide 10: Jennifer Lee
Jennifer Lee EVP, Head of North America ® 10
Slide 11: Label Expansion Expands the Reach of IMCIVREE in the U.S.
Label Expansion Expands the Reach of IMCIVREE in the U.S. 10,000 Patients in the United States 5,000 Patients in the United States 2,500 Patients in the U.S. PPL BBS Acquired HO 2020 2022 2026 NOTE: Estimated prevalence of U.S. patients based on company estimates; does not include ex-U.S. prevalence
Slide 12: Experienced Rare Disease Team in Place to Support Launch
Experienced Rare Disease Team in Place to Support Launch Territory Access team managers supporting in the field reimbursement ® 12
Slide 13: Diagnostic Journey: Meeting the Patients Where They Are
Diagnostic Journey: Meeting the Patients Where They Are 3 Patient’s Obesity is Addressed 2 • All appropriate patients are treated with IMCIVREE Patient Develops Acquired HO • Support patients on therapy • All incident patients are accurately diagnosed within first year of onset • Prevalent patients
Slide 14: Setmelanotide Product Profile Resonates with Endocrinologists
Setmelanotide Product Profile Resonates with Endocrinologists In a hypothetical placebo-controlled trial, how compelling would you find 15% BMI reduction vs 0% for placebo? 94% extremely compelling or compelling 100% would prescribe setmelanotide to patients with HO (N=50) I love seeing that there i
Slide 15: Transformative Day for HO Community
Transformative Day for HO Community Patients waiting First and only Ready to for a therapy approved therapy launch ® 15
Slide 16: Questions
Questions Rhython
Rhythm Pharmaceuticals — Corporate Update (March 2026) on 6ix